WO2020105682A1 - 血中脂質濃度計測装置及びその方法 - Google Patents
血中脂質濃度計測装置及びその方法Info
- Publication number
- WO2020105682A1 WO2020105682A1 PCT/JP2019/045477 JP2019045477W WO2020105682A1 WO 2020105682 A1 WO2020105682 A1 WO 2020105682A1 JP 2019045477 W JP2019045477 W JP 2019045477W WO 2020105682 A1 WO2020105682 A1 WO 2020105682A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- light intensity
- lipid concentration
- light
- amount
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 23
- 210000004369 blood Anatomy 0.000 title claims description 80
- 239000008280 blood Substances 0.000 title claims description 80
- 238000001514 detection method Methods 0.000 claims abstract description 60
- 230000017531 blood circulation Effects 0.000 claims abstract description 36
- 230000003287 optical effect Effects 0.000 claims abstract description 10
- 230000008859 change Effects 0.000 claims description 26
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 abstract description 24
- 108090001030 Lipoproteins Proteins 0.000 description 19
- 102000004895 Lipoproteins Human genes 0.000 description 19
- 239000002245 particle Substances 0.000 description 13
- 108010004103 Chylomicrons Proteins 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000010586 diagram Methods 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 230000000291 postprandial effect Effects 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- -1 lipoprotein exists Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0261—Measuring blood flow using optical means, e.g. infrared light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4866—Evaluating metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
Definitions
- the present invention relates to an apparatus and method for measuring the lipid concentration in blood.
- Controlling healthcare costs for the public is a major issue.
- One-third of medical expenses are occupied by treatment costs for diseases caused by lifestyle-related diseases. Improvement of healthy life expectancy and QOL is required to control the medical expenses of the people. Therefore, the specific medical examination has been implemented, and the way of thinking about non-illness has become widespread.
- metabolic syndrome which is the screening target of specific medical examination, develops diabetes, dyslipidemia, and hypertension caused by metabolic abnormality caused by accumulation of visceral fat obesity. It is expected that early detection of metabolic syndrome will lead to prevention of aggravation, improvement of QOL and control of national medical expenses.
- lipids in blood form micelles covered with amphipathic phospholipids and exist in the form of particles. It is called a lipoprotein because it has lipoproteins bound to its surface.
- Lipoproteins are roughly classified into four types according to their specific gravity. Lipoproteins are classified into chylomicron (CM), VLDL, LDL, and HDL in order of decreasing specific gravity. Further, lipoproteins are classified into CM, VLDL, LDL, and HDL in descending order of particle size.
- Lipoprotein is an aggregate of cholesterol and neutral fat (TG). Blood tests measure triglyceride and cholesterol, which are the smallest units of the constituent components of each lipoprotein.
- LDL cholesterol called bad cholesterol is the concentration of cholesterol contained in LDL particles, and if TG in LDL particles is measured, it becomes LDL-TG.
- LDL cholesterol and HDL cholesterol are known to be indicators related to arteriosclerosis, respectively.
- Postprandial hyperlipidemia has been cited as an important symptom of metabolic measurement.
- Postprandial hyperlipidemia has attracted attention as a risk factor for arteriosclerosis.
- Higher non-fasting triglyceride concentrations have been reported to increase the risk of developing coronary artery events.
- the diagnosis of postprandial hyperlipidemia requires observing changes in blood lipid levels 6-8 hours after a meal. In other words, in order to measure the hyperlipidemic state after eating, it is necessary to restrain the subject for 6 to 8 hours and collect blood multiple times. Therefore, the diagnosis of postprandial hyperlipidemia is beyond the scope of clinical research, and it is not realistic to carry out the diagnosis of postprandial hyperlipidemia in a clinical setting.
- Patent Document 1 A method for solving such a problem is disclosed in Patent Document 1.
- blood lipids can be measured not only at medical institutions but also at home by eliminating blood collection. By enabling immediate data acquisition, it becomes possible to measure blood lipids continuously over time.
- the present invention has been made to solve such conventional problems, and provides an apparatus and method for measuring the absolute value of lipid concentration by non-invasive lipid measurement.
- Blood lipid concentration measuring apparatus of the present invention the angle between the surface of the living body and the optical axis to irradiate the living body with light at a predetermined angle of 45 ° or more and 175 ° or less, and a position at a predetermined distance from the irradiation unit.
- a light intensity detection unit that measures the light intensity reflected from the living body
- a control unit that calculates the turbulence amount of the blood flow based on the light intensity and calculates the lipid concentration based on the turbulence amount of the blood. ..
- the blood lipid concentration measuring method of the present invention an irradiation step of irradiating light to a predetermined position of the living body at a predetermined angle of 45 ° or more and 175 ° or less at an angle formed by the surface of the living body and the optical axis, from a predetermined position.
- the blood lipid concentration measuring device of the present invention According to the blood lipid concentration measuring device of the present invention and the operating method thereof, it is possible to measure the lipid concentration.
- FIG. 1 It is a figure which shows the structure of the blood lipid concentration measuring apparatus of this embodiment. It is a block diagram which shows the structure of the control system of the blood lipid concentration measuring apparatus of this embodiment. It is a figure which shows the scattering of the light by blood lipid. It is a flowchart of the blood lipid concentration measuring method of this embodiment. It is a figure which shows the skin, blood, and muscle contained in the path
- FFT fast Fourier transform
- FIG. 6 is a verification diagram of changes in blood turbidity and incident angles.
- FIG. 6 is a diagram in which individual differences among humans are measured.
- the scattering intensity changes by 0.1 (a.u.)
- it is about 150 mg / dL in TG conversion concentration.
- the current measurement results are compared in absolute value, the value of 400 mg / dL or more will be different between Mr. B and Mr. C in Fig. 6, but the actual difference is about 20 mg / dL from the analysis results after blood collection. There is nothing.
- the present inventor focused on the fact that blood in an actual living body is always flowing, and tried to extract only blood information from the movement of blood.
- FIG. 8 is a diagram showing the results of measuring the time variation of blood scattering coefficient (disturbance of blood flow).
- the time variation of the scattering coefficient the amount of turbulence in the blood flow
- the amplitude of the base of the scattering coefficient increases as the chylomicron concentration increases. You can see that it is getting bigger.
- FIG. 7 is a diagram showing the results of frequency analysis using a fast Fourier transform (FFT) of the results of a non-invasive lipid continuous monitor (6 hours measurement) in a fat load test in order to find the cause of the amplitude of the base. is there.
- FFT fast Fourier transform
- the amplitude seen in Fig. 8 is considered to be the amplitude due to random changes in blood flow. Therefore, the present inventor has noticed turbulent blood flow.
- the Reynolds number of blood flowing through the body is about 2000, and the blood flow is usually laminar. That is, it can be considered that the blood flow is stable and orderly.
- the Reynolds number increases as the density of the substance in the fluid increases, it is considered that the blood flow in the postprandial state has a higher Reynolds number and the state changes from laminar flow to turbulent flow.
- the Reynolds number exceeds 2300, it is said that the laminar flow becomes turbulent, and the blood flow can be said to be near the bifurcation point where laminar flow and turbulent flow are likely to change the state of the flow.
- Fig. 8 shows the results of the fat load test, and it can be confirmed that the vertical width of the base amplitude increases with the increase in chylomicrons. This is probably because turbulence increases in blood vessels due to the increase of large particles such as chylomicrons in the blood.
- the turbulence intensity I (blood flow turbulence) of blood flow in blood vessels can be calculated as follows. First, the fluctuation ⁇ S of the scattering coefficient in the sampling interval ⁇ during noninvasive quality measurement is obtained by the following equation.
- Turbulence intensity I (disturbance of blood flow) is calculated by the following formula.
- FIG. 9 is a diagram showing a result of measuring the time change of the turbulent flow intensity, that is, the turbulent amount of blood flow. As can be seen from FIG. 9, the turbulence of the blood flow was measured, and it was confirmed that there was no individual difference among people.
- Fig. 10 shows the correlation between turbulence intensity (turbulence amount of blood flow) and TG change amount, and a good correlation is obtained with a correlation coefficient of 0.81.
- an evaluation index such as a fluctuation coefficient may be used.
- the accuracy of the information obtained varies depending on the sampling rate of the device. For example, when a periodic light source such as a fluorescent lamp is used as the light source, the accuracy is improved if the sampling rate can measure the period.
- the cycle can be confirmed at a sampling rate of 10 msec, but in this example, the period was 1 msec, and the result is shown in FIG.
- the measurement time is synonymous with the sampling rate.
- the data of the light intensity obtained at the sampling rate may be obtained for several minutes to several tens of minutes, and the obtained light intensity may be averaged.
- data may be constantly acquired and dividedly acquired from the data, and further, data after removing a noise part from the data may be used.
- FIG. 11 shows the time change of the received light intensity when the fat load test is carried out.
- the height of the amplitude fluctuates as the lipid concentration increases. Also, it can be seen that at 120 minutes, the upper and lower portions of the waveform are disturbed and the lower limit is lowered. It is considered that this is because the optical path became uneven as the number of lipid particles increased.
- the absolute value of the lipid concentration can be measured by measuring the turbulent amount of blood flow. As a result, it is possible to expand the intended use and reduce individual differences in lipid concentration measurement.
- FIG. 1 is a block diagram showing the configuration of the blood lipid concentration measuring apparatus of this embodiment.
- the blood lipid concentration measuring device 1 includes an irradiation unit 2 that irradiates irradiation light from outside the living body (A in the drawing) to the living body, and predetermined detection positions 331 and 332 outside the living body.
- the light intensity detection unit 3 (31, 32) for detecting the light intensity in the, and the turbulence amount of blood flow in the living body is calculated based on the light intensity detected by the light intensity detection unit 3, and based on the turbulence amount of blood.
- a control unit 4 for calculating the lipid concentration.
- the irradiation unit 2 has a light source 22 for irradiating a predetermined irradiation position 21 with irradiation light from outside the living body to inside the living body.
- the light source 22 of the present embodiment can adjust the wavelength of irradiation light.
- the light source 22 can adjust the wavelength range to a wavelength range other than the wavelength range in which light is absorbed by the plasma inorganic substance.
- the light source 22 can be adjusted outside the wavelength range in which light is absorbed by the cellular components of blood.
- the cell components of blood are red blood cells, white blood cells, and platelets in blood. Plasma inorganics are water and electrolytes in the blood.
- the irradiation unit 2 of the present embodiment irradiates light such as continuous irradiation of light or pulsed irradiation of light according to the method of calculating the scattering coefficient ⁇ s ′ by the scattering coefficient calculating unit 4 described later.
- the time length can be adjusted arbitrarily.
- the irradiation unit 2 can arbitrarily modulate the intensity or phase of light to be applied.
- the irradiation intensity of the irradiation unit 2 is 0.0025 mW or more and 30 mW or less. By setting the irradiation intensity of the irradiation unit 2 to 0.0025 mW or more, the irradiation light emitted from the living body to the outside of the living body can be detected. Further, from the viewpoint of safety, the irradiation intensity should be 30 mW or less.
- the light intensity detection unit 3 receives the irradiation light emitted from the living body to the outside of the living body and detects the light intensity.
- the light intensity detection units 3 are installed so as to irradiate different positions 331 and 332 with the irradiation position 21 as a substantially center.
- the first light intensity detection unit 31 and the second light intensity detection unit 32 are arranged in order from the irradiation position 21 on the same surface and in a straight line at a predetermined interval. ..
- the light intensity detection unit 3 may be a photodiode or a light receiving element such as CCD or CMOS.
- the distance from the irradiation position 21 to the first detection position 331 by the first light intensity detection unit 31 is defined as the first irradiation detection distance ⁇ 1
- the irradiation position 21 is defined as the second irradiation detection distance ⁇ 2.
- a predetermined distance ⁇ is provided between the irradiation position 21 for irradiating the living body with light and the detection position 31 for detecting the light intensity emitted from the living body (E in the figure).
- the influence of the emitted light (A in the figure) reflected by the surface of the living body and the scatterers near the surface and directly emitted from the living body (B in the figure) is suppressed.
- the irradiated light reaches the depth at which lipid such as lipoprotein exists, the light is reflected by the lipid (D in the figure) in the living blood.
- the irradiation unit 2 is fixed such that an angle ⁇ formed by the optical axis of the irradiation unit 2 and the surface of the living body E is a predetermined angle of 45 ° or more and 175 ° or less.
- the fixed angle of the irradiation unit 2 can be adjusted by an arbitrary mechanism.
- FIG. 14 in order to verify the angle of the irradiation part, a blood vessel-like cavity was opened in a solid phantom, and blood with a varied scattering coefficient was added to the cavity to verify the turbidity change of the blood and the incident angle. It is a thing.
- the depth of the cavity is 1 mm.
- the measured value Intensity (a.u.) here indicates a relative change amount of the light intensity with respect to the light receiving distance.
- a characteristic is that the measurement range is wide at 90 °, for example.
- the angle of the irradiation part is 45 °, the resolution of low value is high, but there are some characteristics such as reaching a peak around the scattering coefficient of 0.5 / mm.
- the angle of the irradiation unit may be selected at a suitable time depending on the characteristics of the subject and may be automatically corrected.
- the angle ⁇ of the irradiation portion in the numerical range of 90 ° or less, 45 ° or more 90 ° or less, more preferably 45 ° or more and 65 ° or less, in the numerical range of 90 ° or more, 100 ° or more 175 ° or less, It is more preferably 115 ° or more and 175 ° or less, still more preferably 135 ° or more and 175 ° or less, and it is preferable to combine these numerical ranges of 90 ° or less with the numerical ranges of 90 ° or more.
- the lipoprotein to be measured has a spherical structure covered with apoprotein and the like. Lipoprotein exists in the blood in a solid-like state. Lipoprotein has a property of reflecting light. In particular, chylomicrons (CM) and VLDL, which have a large particle size and a large specific gravity, contain a large amount of neutral fat (TG) and have the property of more easily scattering light. Therefore, the light intensity detected by the light intensity detection unit 3 includes the influence of light scattering by lipoproteins.
- CM chylomicrons
- VLDL which have a large particle size and a large specific gravity
- the arrangement in the case of providing the plurality of detection positions 31 and 32 is not limited to a linear shape as long as they are arranged at different distances with the irradiation position 21 as a substantial center, and is circular, wavy, or zigzag. Etc. can be appropriately selected.
- the first irradiation detection distance ⁇ 1 from the irradiation position 21 to the detection position 31, the second irradiation detection distance ⁇ 2 from the irradiation position 21 to the detection position 32, and the intervals between the detection positions 331 and 332 are constant.
- the interval is not limited, and may be continuous.
- FIG. 2 is a block diagram of the blood lipid concentration measuring device 1 of the embodiment.
- CPU Central Processing Unit
- ROM Read Only Memory
- RAM Random Access Memory
- HDD Hard Disk Drive
- I / F Interface
- irradiation unit 2 and the light intensity detector 3 Via the system bus 42, CPU (Central Processing Unit) 41, ROM (Read Only Memory) 43, RAM (Random Access Memory) 44, HDD (Hard Disk Drive) 45, external I / F (Interface) 46, irradiation unit 2 and the light intensity detector 3 are connected.
- the CPU 41, the ROM 43, and the RAM 44 constitute the control unit 4.
- the ROM 43 stores in advance a program executed by the CPU 41 and a threshold value.
- the RAM 44 has various memory areas such as an area for developing a program executed by the CPU 41 and a work area which is a work area for data processing by the program.
- the HDD 45 stores data such as a calibration curve created by a plurality of persons for correlating the lipid concentration in the blood of the living body with the disturbance of the light intensity (the disturbance amount of blood flow).
- the external I / F 46 is an interface for communicating with an external device such as a client terminal (PC).
- the external I / F 46 may be an interface that performs data communication with an external device, and may be, for example, a device (USB memory or the like) that is locally connected to the external device, or a network for communicating via a network. It may be an interface.
- the blood lipid concentration measuring device 1 executes a blood lipid concentration measuring job based on a preset program.
- the control unit 4 calculates the scattering coefficient ⁇ s ′ in the living body (including blood, skin, muscle, etc .; the same applies hereinafter) based on the light intensity detected by the light intensity detection unit 3.
- the light intensity detected by the light intensity detection unit 3 includes the influence of light scattering by lipoproteins.
- the scattering coefficient ⁇ s ′ in the present embodiment is not limited to the one that quantifies the efficiency of a general scattering process, and the influence of scattering is quantified under certain conditions in consideration of the scattering phenomenon. Including things.
- the control unit 4 calculates the light intensity ratio or the light intensity difference.
- the control unit 4 calculates the scattering coefficient ⁇ s ′ from the ratio of the light intensities detected by the plurality of light intensity detection units 3.
- the control unit 4 calculates the scattering coefficient ⁇ s ′ based on the scattering phenomenon in which the irradiated light is attenuated by scattering as the distance to the detection position 33 increases.
- the irradiation unit 2 irradiates continuous light of a predetermined light intensity, and the light intensity R ( ⁇ 1) detected by the first light intensity detection unit 31 and the second light intensity detection unit 32 detect it.
- the control unit 4 calculates the scattering coefficient ⁇ s ′ from the difference in the light intensity detected by the plurality of light intensity detection units 3.
- the control unit 4 calculates the scattering coefficient ⁇ s ′ based on the scattering phenomenon in which the irradiated light is attenuated by scattering as the distance to the detection position 33 increases.
- the control unit 4 in the present embodiment calculates the scattering coefficient ⁇ s ′ from the difference between the light intensity R ( ⁇ 1) and the light intensity R ( ⁇ 2) at the first detection position 331 and the second detection position 332. ).
- ⁇ s ' R ( ⁇ 1)-R ( ⁇ 2)
- control unit 4 calculates the scattering coefficient ⁇ s ′ by the control unit 4 .
- the control unit 4 calculates the turbulent flow intensity I (the turbulent amount of blood flow) from the calculated scattering coefficient ⁇ s'.
- the method of calculating the turbulent flow intensity I has been described above.
- the blood lipid concentration of a specific living body is to be measured
- measurement is performed by measuring the change amount of the blood lipid concentration of Mr. A by another blood lipid concentration measuring method such as blood sampling.
- the lipid concentration can be calculated by comparing the result with the calculated turbulence intensity (the amount of turbulence of blood) and creating statistical data of Mr. A.
- the blood lipid concentration of Mr. A is measured by another blood lipid concentration measuring method or the like, and the lipid concentration measurement result obtained by this device is compared and obtained by the comparison.
- the statistical data of Mr. A may be created by calculating an error between the lipid concentration and the lipid concentration in the statistical data in the case of a general living body and performing calibration to correct the error.
- concentration and turbidity are sometimes used interchangeably, and the concept of turbidity is also included in the concentration in this embodiment. Therefore, as the calculation result of the control unit 4, not only the concentration but also the number of particles per unit amount, the formazine turbidity, or the change amount of the average particle size of lipid can be used.
- the format of the statistical data is not particularly limited, and may be classified by, for example, gender, height, weight, BMI, etc., and may be calculated using tables, graphs, functional formulas, etc.
- the control unit 4 can also determine the lipid concentration from the temporal change in the light intensity (the amount of turbulent blood flow) due to the light received by the light intensity detection unit at one point.
- the distance between the irradiation and light receiving parts is around 1.5 to 2 cm.
- One-point measurement is also possible when obtaining turbidity by time-resolved measurement using pulsed light.
- the sampling rate of the light receiving section is more important than the cycle on the light source side. For example, even when data is acquired wirelessly, it is possible to measure the change in turbidity of blood if the sampling rate is 250 times or more per second.
- the measuring time of the light intensity in the light intensity detecting unit 3 is preferably set to 1 msec or more and 20 sec or less.
- the blood lipid concentration measuring device 1 may have a current applying unit that causes a pulse current to flow in the living body.
- the lipid particles are charged, and the zeta potential differs depending on the type of lipoprotein.
- the current application unit causes a pulse current to flow from the outside of the body to the inside of the body to vibrate CM or VLDL. As a result, the scattering coefficient is changed, and the distribution of lipoprotein can be measured more accurately.
- FIG. 4 is a flowchart of the blood lipid concentration measuring method of the present embodiment.
- the irradiation unit 2 is used to irradiate the irradiation position 21 with continuous light.
- the light intensity at the first detection position 331 is detected using the first light intensity detection unit 31, and the second detection position is detected using the second light intensity detection unit 32.
- the light intensity of 332 is detected.
- the light intensities detected at the first detection position 331 and the second detection position 332 are sent to the lipid concentration calculation step.
- the arrangement in the case of providing the plurality of detection positions 31 is not limited to a linear shape as long as they are arranged at different distances with the irradiation position 21 as a substantial center, and may be circular, wavy, zigzag, or the like. It can be appropriately selected. Further, the first irradiation detection distance ⁇ 1 from the irradiation position 21 to the detection position 31, the second irradiation detection distance ⁇ 2, and the intervals between the detection positions 331 and 332 are not limited to constant intervals. It may be continuous.
- the blood concentration of lipid is calculated from the turbulent amount of blood flow.
- the method of calculating the blood concentration of lipid has been described above.
- the blood lipid concentration measuring apparatus and method of the present embodiment it is possible to measure the lipid concentration in blood.
Abstract
Description
(数式1)
μs’=R(ρ1) / R(ρ2)
(数式2)
μs’=R(ρ1) - R(ρ2)
2 照射部
3 光強度検出部
4 制御部
21 照射位置、22 光源、
31 第1の光強度検出部、32 第2の光強度検出部、33 検出位置、331 第1の検出位置、332 第2の検出位置
Claims (9)
- 生体表面と光軸とがなす角が45°以上175°以下の所定の角度で生体に光を照射する照射部と、
前記照射部から所定の距離に位置し、前記生体から反射される光強度を計測する光強度検出部と、
前記光強度に基づき血流の乱れ量を算出し、当該血液の乱れ量に基づいて脂質濃度を算出する、制御部と、
を有する血中脂質濃度計測装置。 - 前記血流の乱れ量は、乱流強度であり、
前記制御部は、
前記乱流強度に基づき前記脂質濃度を算出する、
請求項1に記載の血中脂質濃度計測装置。 - 前記血流の乱れ量は、光強度の変化量であり、
前記制御部は、
前記光強度の変化量に基づき前記脂質濃度を算出する、
請求項1に記載の血中脂質濃度計測装置。 - 前記光強度検出部における前記光強度の変化量の計測時間は1msec以上20sec以下である、請求項3に記載の血中脂質濃度計測装置。
- 前記照射部の角度は、調整可能であることを特徴とする請求項1から4のいずれかに記載の血中脂質濃度計測装置。
- 前記光強度検出部は相異なる位置に複数配置されたことを特徴とする請求項1から5のいずれかに記載の血中脂質濃度計測装置。
- 前記複数の光強度検出部は、円状もしくは直線状に配置された、ことを特徴とする請求項6に記載の血中脂質濃度計測装置。
- 前記照射部の照射強度は、0.0025mW以上30mW以下であることを特徴とする請求項1から7のいずれかに記載の血中脂質濃度計測装置。
- 生体表面と光軸とがなす角が45°以上175°以下の所定の角度で生体の所定の位置に光を照射する照射工程と、
前記所定の位置から所定の距離の位置における前記生体から反射される光強度を計測する光強度検出工程と、
前記光強度に基づき血流の乱れ量を算出し、当該血液の乱れ量に基づいて脂質濃度を算出する脂質濃度算出工程と、
を有する血中脂質濃度計測方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19886131.2A EP3884864A1 (en) | 2018-11-21 | 2019-11-20 | Device for measuring blood lipid concentration and method therefor |
CN201980076679.3A CN113194828A (zh) | 2018-11-21 | 2019-11-20 | 用于测量血液脂质浓度的装置和方法 |
KR1020217017612A KR20210093938A (ko) | 2018-11-21 | 2019-11-20 | 혈중 지질농도 계측장치 및 그 방법 |
JP2020557595A JPWO2020105682A1 (ja) | 2018-11-21 | 2019-11-20 | 血中脂質濃度計測装置及びその方法 |
US17/292,593 US20210401334A1 (en) | 2018-11-21 | 2019-11-20 | Device for measuring blood lipid concentration and method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018218318 | 2018-11-21 | ||
JP2018-218318 | 2018-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020105682A1 true WO2020105682A1 (ja) | 2020-05-28 |
Family
ID=70773833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/045477 WO2020105682A1 (ja) | 2018-11-21 | 2019-11-20 | 血中脂質濃度計測装置及びその方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210401334A1 (ja) |
EP (1) | EP3884864A1 (ja) |
JP (1) | JPWO2020105682A1 (ja) |
KR (1) | KR20210093938A (ja) |
CN (1) | CN113194828A (ja) |
WO (1) | WO2020105682A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6991634B1 (ja) * | 2021-04-13 | 2022-01-12 | メディカルフォトニクス株式会社 | 脂質濃度計測装置、プログラム、及び、方法 |
WO2022138902A1 (ja) * | 2020-12-24 | 2022-06-30 | メディカルフォトニクス株式会社 | 脂質濃度計測装置、プログラム、及び、方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210059575A1 (en) * | 2018-04-26 | 2021-03-04 | Medical Photonics Co., Ltd. | Lipid concentration measurement device and method therefor |
KR102497331B1 (ko) | 2021-07-19 | 2023-02-08 | 엘지전자 주식회사 | 마스크 장치 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016208010A1 (ja) * | 2015-06-24 | 2016-12-29 | 浜松ホトニクス株式会社 | 散乱吸収体測定装置及び散乱吸収体測定方法 |
JP2017113461A (ja) * | 2015-12-25 | 2017-06-29 | 株式会社東芝 | 測定装置、測定方法、およびプログラム |
WO2017141895A1 (ja) * | 2016-02-18 | 2017-08-24 | メディカルフォトニクス株式会社 | 体調管理装置及びその方法 |
WO2017199492A1 (ja) * | 2016-05-18 | 2017-11-23 | メディカルフォトニクス株式会社 | 血中脂質濃度計測装置及びその作動方法 |
WO2018151022A1 (ja) * | 2017-02-14 | 2018-08-23 | メディカルフォトニクス株式会社 | 散乱体計測装置、散乱体計測方法および脂質計測装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3962256B2 (ja) * | 2000-01-18 | 2007-08-22 | ラジオメーター・メディカル・アー・ペー・エス | 装置、試料キュベット、及び光学測定方法 |
US8700111B2 (en) * | 2009-02-25 | 2014-04-15 | Valencell, Inc. | Light-guiding devices and monitoring devices incorporating same |
JP6241853B2 (ja) | 2012-12-06 | 2017-12-06 | 国立大学法人北海道大学 | 非侵襲型生体脂質濃度計測器、非侵襲型生体脂質代謝機能計測器、非侵襲による生体脂質濃度計測方法および非侵襲による生体脂質代謝機能検査方法 |
-
2019
- 2019-11-20 CN CN201980076679.3A patent/CN113194828A/zh not_active Withdrawn
- 2019-11-20 KR KR1020217017612A patent/KR20210093938A/ko unknown
- 2019-11-20 EP EP19886131.2A patent/EP3884864A1/en not_active Withdrawn
- 2019-11-20 US US17/292,593 patent/US20210401334A1/en active Pending
- 2019-11-20 WO PCT/JP2019/045477 patent/WO2020105682A1/ja unknown
- 2019-11-20 JP JP2020557595A patent/JPWO2020105682A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016208010A1 (ja) * | 2015-06-24 | 2016-12-29 | 浜松ホトニクス株式会社 | 散乱吸収体測定装置及び散乱吸収体測定方法 |
JP2017113461A (ja) * | 2015-12-25 | 2017-06-29 | 株式会社東芝 | 測定装置、測定方法、およびプログラム |
WO2017141895A1 (ja) * | 2016-02-18 | 2017-08-24 | メディカルフォトニクス株式会社 | 体調管理装置及びその方法 |
WO2017199492A1 (ja) * | 2016-05-18 | 2017-11-23 | メディカルフォトニクス株式会社 | 血中脂質濃度計測装置及びその作動方法 |
WO2018151022A1 (ja) * | 2017-02-14 | 2018-08-23 | メディカルフォトニクス株式会社 | 散乱体計測装置、散乱体計測方法および脂質計測装置 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138902A1 (ja) * | 2020-12-24 | 2022-06-30 | メディカルフォトニクス株式会社 | 脂質濃度計測装置、プログラム、及び、方法 |
JP6991634B1 (ja) * | 2021-04-13 | 2022-01-12 | メディカルフォトニクス株式会社 | 脂質濃度計測装置、プログラム、及び、方法 |
WO2022220209A1 (ja) * | 2021-04-13 | 2022-10-20 | メディカルフォトニクス株式会社 | 脂質濃度計測装置、プログラム、及び、方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3884864A1 (en) | 2021-09-29 |
CN113194828A (zh) | 2021-07-30 |
KR20210093938A (ko) | 2021-07-28 |
US20210401334A1 (en) | 2021-12-30 |
JPWO2020105682A1 (ja) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020105682A1 (ja) | 血中脂質濃度計測装置及びその方法 | |
US11331012B2 (en) | Non-invasive biolipid concentration meter, non-invasive biolipid metabolism measuring device, non-invasive method for measuring biolipid concentration, and non-invasive method for examining biolipid metabolism | |
US10863934B2 (en) | Blood lipid concentration measurement device and method for operating same | |
US11000214B2 (en) | Physical condition management device and method for same | |
WO2019225612A1 (ja) | 血管検知装置及びその方法 | |
TWI773713B (zh) | 脂質測量裝置及其方法 | |
WO2019208718A1 (ja) | 脂質濃度計測装置及びその方法 | |
RU2413930C1 (ru) | Способ определения оптических характеристик однородного рассеивающего вещества | |
JP2022149431A (ja) | 総蛋白濃度計測装置及びその方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19886131 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020557595 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217017612 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019886131 Country of ref document: EP Effective date: 20210621 |